Skip to main content
. 2017 Aug 24;174(20):3608–3622. doi: 10.1111/bph.13961

Figure 4.

Figure 4

The combination of YF454A and erlotinib synergistically suppresses the growth of EGFR‐TKI resistant tumour xenografts in vivo. (A, B) The combination of YF454A and erlotinib inhibited the growth of primary EGFR‐TKI‐resistant A549 xenografts (n = 8). Nude mice bearing A549 tumours were treated with different drugs or drug combinations. The tumour volume in mice was plotted every 3 days (A), and tumour weights were measured when the mice were killed on day 28 (B). (C, D) The tumour growth of acquired EGFR‐TKI‐resistant PC9/ER xenografts (n = 11 in the vehicle control group, erlotinib group and YF454A group; n = 10 in the combination group) was dramatically suppressed by the co‐treatment with YF454A and erlotinib, as indicated by tumour volume curves (C) and tumour weights in different groups on day 28 (D). Means are shown with bars representing SEM. One‐way ANOVA with Turkey's post hoc tests were performed; *P < 0.05 significantly different as indicated. See also Supporting Information Figure S3.